A topical hedgehog pathway inhibitor. Phase 2 and 3 trials assessing the effectiveness of patidegib in patients with Gorlin syndrome or non-Gorlin basal cell carcinoma are ongoing.[91]ClinicalTrials.gov. Study of patidegib topical gel, 2%, for the reduction of disease burden of persistently developing basal cell carcinomas (BCCs) in subjects with basal cell nevus syndrome (Gorlin syndrome). NCT03703310. Mar 2021 [internet publication].
https://clinicaltrials.gov/ct2/show/NCT03703310
[92]ClinicalTrials.gov. Trial of patidegib gel 2%, 4%, and vehicle to decrease the number of surgically eligible basal cell carcinomas in Gorlin syndrome patients. NCT02762084. Jul 2020 [internet publication].
https://clinicaltrials.gov/ct2/show/NCT02762084
[93]ClinicalTrials.gov. Clinical trial of patidegib gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). NCT02828111. Jan 2019 [internet publication].
https://clinicaltrials.gov/ct2/show/NCT02828111